- Home
- ALEC vs JCE Comparison
ALEC vs JCE Comparison
Compare ALEC & JCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALEC | JCE |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 245.4M | 252.8M |
| IPO Year | 2019 | 2007 |
Fundamental Metrics
Financial Performance| Metric | ALEC | JCE |
|---|---|---|
| Price | $2.17 | $16.52 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $4.83 | N/A |
| AVG Volume (30 Days) | ★ 593.7K | 26.4K |
| Earning Date | 05-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $21,045,000.00 | N/A |
| Revenue This Year | $2.03 | N/A |
| Revenue Next Year | $29.87 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.09 | $13.99 |
| 52 Week High | $3.40 | $16.68 |
Technical Indicators
Market Signals| Indicator | ALEC | JCE |
|---|---|---|
| Relative Strength Index (RSI) | 44.57 | 68.67 |
| Support Level | $1.93 | $15.31 |
| Resistance Level | $2.64 | N/A |
| Average True Range (ATR) | 0.16 | 0.19 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 41.10 | 86.21 |
Price Performance
Historical ComparisonAbout ALEC Alector Inc.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.
About JCE Nuveen Core Equity Alpha Fund of Beneficial Interest
Nuveen Core Equity Alpha Fund is a diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the S&P 500 Index. The Fund invests in a portfolio of actively managed large-capitalization U.S. common stocks, using the sub-adviser's proprietary quantitative process designed to provide the potential for long-term outperformance. Additionally, the Fund seeks to reduce the volatility of its returns relative to the returns of the Equity Portfolio over extended periods by writing (selling) index call options and/or call options on custom baskets of securities.